|
The Immunohistochemistry Antibody Company
|
|
|
General Cancer Screen 173 Tissue Microarray - LS-SCA173This tissue microarray is available for use in LSBio Immunohistochemistry Studies only. |
| Catalog ID: | LS-SCA173 |
| Product Name: | General Cancer Screen 173 |
| Description: | Various organ normal and diseased tissues |
| Format: | FFPE |
| Category: | Human Tumor and Normal |
| QA/QC: | H&E reviewed; IHC validated with a positive control antibody |
| Storage: | Short term RT; Long term 4ºC |
| Clinical History: | No |
| Tissue Marker: | No |
| Stage/Grade: | Yes |
| Core Diameter: | 1.5 mm |
| Core Thickness: | 5 µm |
| Cases: | 54 |
| Cores: | 60 |
| Slides Per Set: | 1 |
LS-SCA173 Tissue Microarray Map
Slide Number 1
| LABEL |
|
Diagnosis Type Legend
| Benign non-neoplastic | Diseased | Inflammatory | Malignant | Metastatic | Tumor | Unknown |
Element Tissue Legend
Breast (Bst); Breast, Fibrofatty tissue (Bst); Cervix (Cvx); Colon (Col); Esophagus (Eso); Kidney (Kid); Liver (Liv); Lung (Lng); Ovary (Ova); Ovary, Smooth muscle (Ova); Rectum (Rec); Rectum, Fibrofatty tissue (Rec); Stomach (Sto);
LS-SCA173 Element Details
| Slide | Position | Species | Gender | Age | Tissue | Diagnosis | Diagnosis Type | Tumor Grade |
|---|---|---|---|---|---|---|---|---|
| 1 | A1 | Human | M | 62 y | Esophagus (Eso) | Squamous cell carcinoma | Malignant | Grade III |
| 1 | A2 | Human | M | 56 y | Esophagus (Eso) | Squamous cell carcinoma | Malignant | Grade III |
| 1 | A3 | Human | M | 48 y | Esophagus (Eso) | Squamous cell carcinoma | Malignant | Grade III |
| 1 | A4 | Human | F | 55 y | Stomach (Sto) | Inflammation | Inflammatory | |
| 1 | A5 | Human | M | 57 y | Stomach (Sto) | Adenocarcinoma | Malignant | Grade III |
| 1 | A6 | Human | M | 74 y | Stomach (Sto) | Adenocarcinoma | Malignant | Grade III |
| 1 | A7 | Human | M | 37 y | Colon (Col) | Adenocarcinoma | Malignant | Grade II |
| 1 | A8 | Human | M | 62 y | Colon (Col) | Adenocarcinoma | Malignant | Grade II |
| 1 | A9 | Human | M | 58 y | Colon (Col) | Adenocarcinoma | Malignant | Grade II |
| 1 | A10 | Human | M | 62 y | Esophagus (Eso) | Inflammation | Inflammatory | |
| 1 | B1 | Human | F | 72 y | Esophagus (Eso) | Normal | Benign non-neoplastic | |
| 1 | B2 | Human | M | 54 y | Esophagus (Eso) | Inflammation | Inflammatory | |
| 1 | B3 | Human | F | 55 y | Stomach (Sto) | Normal | Benign non-neoplastic | |
| 1 | B4 | Human | M | 57 y | Stomach (Sto) | Normal | Benign non-neoplastic | |
| 1 | B5 | Human | M | 66 y | Stomach (Sto) | Normal | Benign non-neoplastic | |
| 1 | B6 | Human | F | 56 y | Colon (Col) | Normal | Benign non-neoplastic | |
| 1 | B7 | Human | M | 62 y | Colon (Col) | Inflammation | Inflammatory | |
| 1 | B8 | Human | M | 58 y | Colon (Col) | Inflammation | Inflammatory | |
| 1 | B9 | Human | M | 55 y | Rectum (Rec) | Adenocarcinoma | Malignant | Grade I |
| 1 | B10 | Human | M | 67 y | Rectum (Rec) | Adenocarcinoma | Malignant | Grade I |
| 1 | C1 | Human | F | 55 y | Rectum (Rec) | Adenocarcinoma | Malignant | Grade I |
| 1 | C2 | Human | F | 32 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | Grade II |
| 1 | C3 | Human | M | 39 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | Grade II |
| 1 | C4 | Human | F | 55 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | Grade II |
| 1 | C5 | Human | M | 66 y | Lung (Lng) | Squamous cell carcinoma | Malignant | Grade II |
| 1 | C6 | Human | F | 59 y | Lung (Lng) | Squamous cell carcinoma | Malignant | Grade II |
| 1 | C7 | Human | M | 55 y | Lung (Lng) | Squamous cell carcinoma | Malignant | Grade II |
| 1 | C8 | Human | M | 68 y | Colon (Col) | Normal | Benign non-neoplastic | |
| 1 | C9 | Human | F | 58 y | Rectum (Rec) | Normal | Benign non-neoplastic | |
| 1 | C10 | Human | M | 67 y | Rectum, Fibrofatty tissue (Rec) | Normal | Benign non-neoplastic | |
| 1 | D1 | Human | M | 63 y | Liver (Liv) | Fatty degeneration | Diseased | |
| 1 | D2 | Human | F | 66 y | Liver (Liv) | Inflammation | Inflammatory | |
| 1 | D3 | Human | M | 48 y | Liver (Liv) | Inflammation | Inflammatory | |
| 1 | D4 | Human | F | 69 y | Lung (Lng) | Normal | Benign non-neoplastic | |
| 1 | D5 | Human | F | 43 y | Lung (Lng) | Normal | Benign non-neoplastic | |
| 1 | D6 | Human | M | 65 y | Lung (Lng) | Normal | Benign non-neoplastic | |
| 1 | D7 | Human | M | 72 y | Kidney (Kid) | Clear cell carcinoma | Malignant | Grade I |
| 1 | D8 | Human | M | 50 y | Kidney (Kid) | Clear cell carcinoma | Malignant | Grade I |
| 1 | D9 | Human | M | 54 y | Kidney (Kid) | Clear cell carcinoma | Malignant | Grade I |
| 1 | D10 | Human | F | 29 y | Breast (Bst) | Adenosis | Diseased | |
| 1 | E1 | Human | F | 45 y | Breast (Bst) | Ductal carcinoma, infiltrating | Malignant | |
| 1 | E2 | Human | F | 52 y | Breast (Bst) | Ductal carcinoma, infiltrating | Malignant | |
| 1 | E3 | Human | F | 76 y | Cervix (Cvx) | Transitional cell carcinoma | Malignant | |
| 1 | E4 | Human | F | 47 y | Cervix (Cvx) | Transitional cell carcinoma | Malignant | |
| 1 | E5 | Human | F | 42 y | Cervix (Cvx) | Transitional cell carcinoma | Malignant | |
| 1 | E6 | Human | M | 54 y | Kidney (Kid) | Normal | Benign non-neoplastic | |
| 1 | E7 | Human | F | 61 y | Kidney (Kid) | Normal | Benign non-neoplastic | |
| 1 | E8 | Human | F | 47 y | Kidney (Kid) | Normal | Benign non-neoplastic | |
| 1 | E9 | Human | F | 43 y | Breast, Fibrofatty tissue (Bst) | Normal | Benign non-neoplastic | |
| 1 | E10 | Human | F | 39 y | Breast (Bst) | Normal | Benign non-neoplastic | |
| 1 | F1 | Human | F | 54 y | Breast (Bst) | Adenosis | Diseased | |
| 1 | F2 | Human | F | 73 y | Breast (Bst) | Normal | Benign non-neoplastic | |
| 1 | F3 | Human | F | 50 y | Breast (Bst) | Normal | Benign non-neoplastic | |
| 1 | F4 | Human | F | 43 y | Breast (Bst) | Normal | Benign non-neoplastic | |
| 1 | F5 | Human | F | 56 y | Ovary (Ova) | Adenocarcinoma, Serous and papillary | Malignant | Grade III |
| 1 | F6 | Human | F | 49 y | Ovary (Ova) | Adenocarcinoma, Serous and papillary | Malignant | Grade III |
| 1 | F7 | Human | F | 24 y | Ovary (Ova) | Adenocarcinoma, Serous and papillary | Malignant | Grade III |
| 1 | F8 | Human | F | 40 y | Ovary (Ova) | Normal | Benign non-neoplastic | |
| 1 | F9 | Human | F | 39 y | Ovary (Ova) | Normal | Benign non-neoplastic | |
| 1 | F10 | Human | F | 31 y | Ovary, Smooth muscle (Ova) | Normal | Benign non-neoplastic |